<DOC>
	<DOCNO>NCT01872039</DOCNO>
	<brief_summary>To compare efficacy safety two dose adjustment regimen ( i.e . weight-based non-weight-based ) treatment Chinese hypertensive emergency patient .</brief_summary>
	<brief_title>Post Marketing Study Evaluate Two Dose Regimens Nicardipine Injection Hypertensive Emergency Patients</brief_title>
	<detailed_description>This study prospective , multi-center , open-label , randomize control study . Subjects select hypertensive emergency patient BP ( Blood Pressure ) &gt; 180/120mmHg ( SBP/DBP ) accompany end target organ damage . All subject randomize two group receive Nicardipine Injection : Control Group ( weight-based dose adjustment , i.e . accord current Package Insert approve SFDA ) Study Group ( non-weight-based dose adjustment , i.e . accord Package Insert approve FDA ) . Patients meet inclusion/exclusion criterion randomly allocate 1:1 proportion Control Group Study Group . Before treatment , investigator define target BP value every subject accord different illness state , According BP , dose Nicardipine Injection adjust different method reach target BP value . After reach target BP value 60min dose initiation , BP pulse rate measure every 5~15min 2h . Two six hour dose , BP control 160/100~110mmHg , maintenance dose determine investigator accord illness state .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Emergencies</mesh_term>
	<mesh_term>Nicardipine</mesh_term>
	<criteria>Systolic blood pressure ( SBP ) ≥180mmHg and/or diastolic blood pressure ( DBP ) ≥120mmHg , evidence manifestation endorgan damage ( i.e . follow hypertension emergency symptom : Chest pain , short breath , upper abdominal discomfort , syncope , vertigo , blur vision , consciousness , hematuria ischemic change 12lead ECG ) Able voluntary complete study accord study protocol , sign Informed Consent Form himself/herself ( via his/her legal guardian ) Allergy Nicardipine Injection composition Serious aortic valve stenosis Perioperative hypertension Cerebral hemorrhage cause cerebrovascular malformation , hemangioma cerebral infarction , cerebral hemorrhage cerebral ventricle , cerebral trauma concomitant cerebral hemorrhage Other possible influence factor safety efficacy judgment investigator ' opinion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Nicardipine</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Calcium blocker</keyword>
</DOC>